Sorafenib in Urothelium Cancer of Bladder

This study has been terminated.
(Slow recruitment)
Sponsor:
Collaborator:
University Hospital, Essen (Sponsor)
Information provided by (Responsible Party):
Association of Urogenital Oncology (AUO)
ClinicalTrials.gov Identifier:
NCT01215266
First received: October 1, 2010
Last updated: September 7, 2011
Last verified: September 2011

October 1, 2010
September 7, 2011
October 2006
June 2011   (final data collection date for primary outcome measure)
Progression free survival [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01215266 on ClinicalTrials.gov Archive Site
  • Response rates, time of response [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Time to progression [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Evaluation and comparison in both treatment arms [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Sorafenib in Urothelium Cancer of Bladder
Prospektiv, Randomisierte, Doppelblinde, Multizentrische Phase-II- Studie Zum Vergleich Der Wirksamkeit Einer Chemotherapie Mit Gemcitabin Plus Cisplatin Und Sorafenib (BAY 43-9006) Versus Gemcitabin Plus Cisplatin Und Plazebo in Der Therapie Des Lokal Fortgeschrittenen Bzw. Metastasierten Urothelkarzinoms AB 31/05 - RUTT 204 - SUSE

The purpose of this study is to evaluate the use of Sorafenib additionally to gemcitabine and cisplatin in bladder cancer.

A controlled, double-blind, randomized study to evaluate the influence of Sorafenib in bladder cancer patients additionally to chemotherapy with gemcitabine and cisplatin compared to placebo.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Bladder Cancer
  • Drug: Sorafenib
    Day 3-21 2x2 800 mg(milligram) daily
    Other Name: Prüfsubstanz
  • Drug: Placebo
    Day 3-21 2x2 800 mg(milligram) daily
    Other Name: Plazebo
  • Active Comparator: Sorafenib
    Intervention: Drug: Sorafenib
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
98
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

Men and Women > 18 years

  • Condition ECOG(Eastern Cooperative Oncology Group) 0-1
  • Life expectancy at least 12 weeks
  • Women in conceptional age: negative pregnancy test and adequate contraception (oral contraceptive, spiral); at men adequate contraception of the man (condom use) to 3 months after discontinuation of therapy with sorafenib
  • Histologically or cytologically proven urothelial carcinoma of the bladder or upper urinary tract
  • Locally advanced or metastatic urothelial carcinoma of the bladder or upper urinary tract (T3b,T4/ N+/M+)
  • At least one unidimensional measurable lesion on CT(Computed Tomography) or MRI(Magnetic resonance imaging) according to RECIST(Response Evaluation Criteria in Solid Tumors) criteria
  • Adequate hematologic, renal, hepatic and coagulation-physiological functions
  • Leukocytes > 1.500 cells /ml (per milliliter)
  • Hemoglobin >9g/dl(gram per deciliter)
  • Platelet > 100000 /ml
  • Serum creatinine < 2 x upper limit of normal or creatinine clearance ≥ 45 ml/min (milliliter per minute)
  • Total Bilirubin < 1,5 x upper limit of normal
  • GOT/GPT (glutamate-oxalacetate-transaminase/glutamate-pyruvate-transaminase) < 2,5 x upper limit of normal, at liver metastases < 5x upper limit of normal
  • alkaline phosphates < 5 x upper limit of normal
  • Amylase/ Lipase < 1,5 x upper limit of normal
  • INR(International Normalized Ratio) und PTT(Partial Thromboplastin Time) < 1,5 x upper limit of normal
  • Informing the patient about the study and the present written consent to participate after clarification in accordance with the stipulations of AMG(german drug law), and the principles of the Ethics Committee ("informed consent").

Exclusion Criteria:

  • Absence of the above inclusion criteria
  • Dialysis after nephrectomy
  • Patients with brain tumors and / or brain metastases
  • Previous or existing serious cardiovascular (grade III - IV according to NYHA(New York Heart Association)) disease, active angina pectoris or ischemia, myocardial infarction within 6 months prior to enrollment, or patients with serious cardiac arrhythmias requiring antiarrhythmic therapy (beta blockers and digoxin are permitted)
  • Patients with uncontrolled high blood pressure, systolic blood pressure> 150 mm Hg or diastolic pressure> 90 mmHg despite optimal medical treatment
  • Patients with thrombotic or embolic events such as stroke or pulmonary embolism
  • Patients with recently or known bleeding diathesis
  • Known significant neurological or psychiatric diseases including dementia and epileptic seizures
  • Serious inflammatory eye disease, hearing impairment
  • Pulmonary (pO2(Blood oxygen) <60 mm Hg(Millimeters of mercury)), hematopoietic (eg(exempli gratia) severe bone marrow aplasia), hepatic or renal disease
  • Patients with poorly controlled diabetes mellitus
  • Serious bacterial or fungal infections(>Grade 2 NCI-CTC(National Cancer Institute-Common Terminology Criteria) Version 3)
  • chronic hepatitis B or C, HIV(human immunodeficiency virus) infection
  • Autoimmune disease
  • Allergic reactions to be used in respect of a drug
  • prior organ transplantation
  • prior autologous bone marrow transplant or stem cell transferred within the last 4 months before study
  • Manifesto, second malignancy or other malignancy within the past 5 years (except basal cell carcinoma, carcinoma in situ of the cervix, incidental prostate carcinoma)
  • Pregnancy or breast-feeding
  • Lack of cooperation and the ability to cooperate, predictable problems with the aftercare, psychiatric disorders, substance abuse, lack of capacity of the patient
  • Participation in other treatment studies in the last 4 weeks
  • Previous treatment with chemotherapy or immunotherapy
  • Simultaneous treatment with other anti-tumor therapies after study start
  • Intravesical chemotherapy within the last 4 weeks
  • Irradiation within the last 4 weeks
  • Previous radiation therapy, when all were irradiated to the assessment of tumor response used lesions
  • Complex operations, open biopsy or significant injuries within the last 4 weeks before study
  • Serious wound healing disorder, ulcers or bone fractures in the last 4 weeks before study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01215266
AB 31/05 RUTT 204, 2005-006098-29
Yes
Association of Urogenital Oncology (AUO)
Association of Urogenital Oncology (AUO)
University Hospital, Essen (Sponsor)
Study Chair: Susanne Krege, Prof. Dr. Universität Duisburg-Essen
Association of Urogenital Oncology (AUO)
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP